Nav: Home

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer

January 09, 2019

Aggressive prostate cancer, one of the leading causes of cancer deaths in men, is associated with BRCA2 mutations, which are also linked to hereditary breast cancer, ovarian cancer and pancreas cancer, among others. The finding was confirmed in a study, published in the Journal of Clinical Oncology, led by Elena Castro, Nuria Romero-Laorden and David Olmos, from the Prostate Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO). It reveals that family members of patients with prostate cancer who carry BRCA2 and DNA-repair gene mutations have an increased risk of developing cancer and should be evaluated in familial cancer prevention programmes.

Furthermore, the new study shows that prostate cancer in men with BRCA2 mutations is associated with worse outcomes and poor responses to standard treatments. Researchers are currently assessing the benefits of ovarian and breast cancer therapies for prostate cancer patients.

The recently published article reports the first results of PROREPAIR-B, a study coordinated by CNIO researchers and conducted at the Instituto de Investigacion Biomedica de Malaga (IBIMA) and the Instituto de Genetica Medica y Molecular (INGEMM), with the participation of 38 Spanish hospitals. More than 400 men diagnosed with prostate cancer resistant to castration -- or hormone blockade -- were followed up for five years starting in 2013 in order to analyse their genetic characteristics and the impact of these on the progression of the disease and response to treatments.

"This is the first prospective study -- that is, not looking back in time but watching for outcomes from the moment patients are diagnosed with advanced cancer -- that shows BRCA2 mutations themselves, regardless of other factors, are responsible for poor prognosis and can have an impact on treatment responses," explains Castro, the article's first author.

"It should be noted that we identified germline mutations, although in a number of patients there were no familial cancer cases that might have indicated the presence of such genetic alterations. These mutations should be identified in patients with metastatic prostate cancer, since detecting such alterations is important for the diagnosis and management of the disease and for the patients' families, whose risk of developing breast, ovarian or pancreatic cancer is increased," explains Castro.

PROREPAIR-B is the first prospective cohort study carried out for a long period that involves a large number of patients diagnosed with metastatic prostate cancer castration resistant and with hereditary alterations.

"Our study shows that treatment and follow-up protocols used in patients with advanced prostate cancer may be inadequate for men with BRCA2 mutations. We are currently studying the characteristics that make these tumours more aggressive and trying to establish new strategies to improve patient prognosis," says David Olmos, Head of the CNIO Prostate Cancer Clinical Research Unit and coordinator of the project.

PROREPAIR-B: the genetics of the most aggressive prostate cancer

Prostate cancer is the most frequent cancer among males in Spain and Western countries, and the second most frequent worldwide. In recent years, survival has gradually increased as a result of early detection; however, it is the third most common cause of cancer deaths in men in Europe.

Most tumours are detected early, which improves prognosis. Advanced prostate cancer is usually treated with hormone therapy; however, a number of patients develop castration resistant prostate cancer. Some of these patients show poor responses to standard treatments. In general, survival in patients with resistance to androgen deprivation therapy is 3 years on average.

One of the main goals of PROREPAIR-B is to identify genetic markers associated to poor prognosis. In addition, understanding the genetic traits of aggressive tumours can help to explore novel treatment pathways.

The study focuses mainly on genetic patterns associated to deficiencies in DNA-repair mechanisms. Tumour cells carry many more genetic alterations than normal cells, which means they need highly effective repair mechanisms. According to Castro, her team "knew DNA repair is extremely important in prostate cancer. What we did not know was the proportion of patients in the population with advanced stage disease and hereditary mutations."

The study shows that 3% of the patients carry BRCA2 mutations, a percentage that reaches 16% when all DNA-repair genes are considered. "This proportion may seem comparatively low but it comprises a significant number of patients, given the high incidence of prostate cancer," says Castro.

A new treatment pathway

The researchers who participated in the study believe treatment strategies should be improved by optimising existing therapies and finding new drugs. In some patients, drugs interfering with DNA-repair mechanisms might be effective, as the cells that cannot repair their genetic defects die.

These drugs are PARP inhibitors, which have been approved for ovarian cancer and whose efficiency in prostate cancer is currently being tested in a number of clinical trials. Carboplatin is another drug that is currently being used to treat breast and ovarian cancers. The US Department of Defense has awarded funds to support a clinical trial carried out in Spain to demonstrate the effectiveness of carboplatin in patients with prostate cancer and DNA-repair defects.
-end-
PROREPAIR B is part of PROCURE, a project developed at the CNIO Prostate Cancer Clinical Research Unit that consists of multiple prospective studies to evaluate biomarkers. A large number of Spanish researchers are participating in this multicentre project, which has gathered one of Europe's largest sample collections from advanced prostate cancer patients.

PROREPAIR-B received funding from the Prostate Cancer Foundation, CRIS Cancer Foundation, the Health Institute Carlos III, the Spanish Ministry of Science, Innovation and Universities, the Spanish Ministry of Education, Culture and Sports and the Spanish Association Against Cancer.

Reference article: PROREPAIR-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of metastatic castration resistant prostate cancer patients. Elena Castro et al (Journal of Clinical Oncology, 2019). DOI: 10.1200/JCO.18.00358

Centro Nacional de Investigaciones Oncológicas (CNIO)

Related Prostate Cancer Articles:

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.
The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.
Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.
First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.
Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.
Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.
Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.
ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer.
Patient prostate tissue used to create unique model of prostate cancer biology
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
More Prostate Cancer News and Prostate Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Making Amends
What makes a true apology? What does it mean to make amends for past mistakes? This hour, TED speakers explore how repairing the wrongs of the past is the first step toward healing for the future. Guests include historian and preservationist Brent Leggs, law professor Martha Minow, librarian Dawn Wacek, and playwright V (formerly Eve Ensler).
Now Playing: Science for the People

#566 Is Your Gut Leaking?
This week we're busting the human gut wide open with Dr. Alessio Fasano from the Center for Celiac Research and Treatment at Massachusetts General Hospital. Join host Anika Hazra for our discussion separating fact from fiction on the controversial topic of leaky gut syndrome. We cover everything from what causes a leaky gut to interpreting the results of a gut microbiome test! Related links: Center for Celiac Research and Treatment website and their YouTube channel
Now Playing: Radiolab

The Flag and the Fury
How do you actually make change in the world? For 126 years, Mississippi has had the Confederate battle flag on their state flag, and they were the last state in the nation where that emblem remained "officially" flying.  A few days ago, that flag came down. A few days before that, it coming down would have seemed impossible. We dive into the story behind this de-flagging: a journey involving a clash of histories, designs, families, and even cheerleading. This show is a collaboration with OSM Audio. Kiese Laymon's memoir Heavy is here. And the Hospitality Flag webpage is here.